Alkermes (ALKS) Competitors $29.47 -0.28 (-0.94%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends ALKS vs. UTHR, NBIX, INCY, BMRN, EXAS, EXEL, RGEN, HALO, MDGL, and IONSShould you be buying Alkermes stock or one of its competitors? The main competitors of Alkermes include United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Exact Sciences (EXAS), Exelixis (EXEL), Repligen (RGEN), Halozyme Therapeutics (HALO), Madrigal Pharmaceuticals (MDGL), and Ionis Pharmaceuticals (IONS). These companies are all part of the "biotechnology" industry. Alkermes vs. United Therapeutics Neurocrine Biosciences Incyte BioMarin Pharmaceutical Exact Sciences Exelixis Repligen Halozyme Therapeutics Madrigal Pharmaceuticals Ionis Pharmaceuticals Alkermes (NASDAQ:ALKS) and United Therapeutics (NASDAQ:UTHR) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their community ranking, valuation, institutional ownership, earnings, media sentiment, risk, profitability, analyst recommendations and dividends. Does the media favor ALKS or UTHR? In the previous week, United Therapeutics had 11 more articles in the media than Alkermes. MarketBeat recorded 13 mentions for United Therapeutics and 2 mentions for Alkermes. United Therapeutics' average media sentiment score of 1.29 beat Alkermes' score of 0.88 indicating that United Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alkermes 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive United Therapeutics 10 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer ALKS or UTHR? Alkermes currently has a consensus price target of $36.00, suggesting a potential upside of 22.16%. United Therapeutics has a consensus price target of $378.36, suggesting a potential upside of 5.41%. Given Alkermes' higher probable upside, equities analysts plainly believe Alkermes is more favorable than United Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alkermes 1 Sell rating(s) 2 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.64United Therapeutics 1 Sell rating(s) 2 Hold rating(s) 12 Buy rating(s) 0 Strong Buy rating(s) 2.73 Which has better earnings and valuation, ALKS or UTHR? United Therapeutics has higher revenue and earnings than Alkermes. Alkermes is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlkermes$1.66B2.87$355.76M$1.9515.11United Therapeutics$2.76B5.81$984.80M$22.7715.76 Is ALKS or UTHR more profitable? United Therapeutics has a net margin of 40.31% compared to Alkermes' net margin of 22.15%. Alkermes' return on equity of 24.92% beat United Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Alkermes22.15% 24.92% 14.55% United Therapeutics 40.31%19.22%16.15% Do institutionals & insiders hold more shares of ALKS or UTHR? 95.2% of Alkermes shares are owned by institutional investors. Comparatively, 94.1% of United Therapeutics shares are owned by institutional investors. 4.9% of Alkermes shares are owned by insiders. Comparatively, 11.9% of United Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Does the MarketBeat Community favor ALKS or UTHR? Alkermes received 103 more outperform votes than United Therapeutics when rated by MarketBeat users. Likewise, 70.51% of users gave Alkermes an outperform vote while only 62.50% of users gave United Therapeutics an outperform vote. CompanyUnderperformOutperformAlkermesOutperform Votes69870.51% Underperform Votes29229.49% United TherapeuticsOutperform Votes59562.50% Underperform Votes35737.50% Which has more volatility & risk, ALKS or UTHR? Alkermes has a beta of 0.49, indicating that its stock price is 51% less volatile than the S&P 500. Comparatively, United Therapeutics has a beta of 0.57, indicating that its stock price is 43% less volatile than the S&P 500. SummaryUnited Therapeutics beats Alkermes on 13 of the 18 factors compared between the two stocks. Get Alkermes News Delivered to You Automatically Sign up to receive the latest news and ratings for ALKS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALKS vs. The Competition Export to ExcelMetricAlkermesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.77B$6.22B$5.21B$9.14BDividend YieldN/A2.94%5.13%4.02%P/E Ratio15.119.8789.3417.36Price / Sales2.87309.211,240.0477.11Price / Cash12.3761.4443.7535.97Price / Book4.096.055.314.79Net Income$355.76M$154.90M$122.54M$225.00M7 Day Performance3.95%-0.32%0.59%2.62%1 Month Performance-0.81%0.43%2.55%3.81%1 Year Performance5.63%3.08%25.29%20.10% Alkermes Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALKSAlkermes4.5126 of 5 stars$29.47-0.9%$36.00+22.2%+5.6%$4.77B$1.66B15.112,100Short Interest ↓UTHRUnited Therapeutics4.9186 of 5 stars$365.41+0.1%$378.36+3.5%+64.8%$16.31B$2.76B16.05980Positive NewsNBIXNeurocrine Biosciences4.8693 of 5 stars$142.65+1.2%$164.81+15.5%+4.3%$14.44B$2.24B38.241,200Insider TradeINCYIncyte4.7782 of 5 stars$72.62+2.9%$76.29+5.1%+17.0%$13.99B$4.08B518.752,524Short Interest ↓BMRNBioMarin Pharmaceutical4.9986 of 5 stars$66.99-0.6%$94.20+40.6%-33.3%$12.77B$2.75B40.113,401Options VolumeEXASExact Sciences4.797 of 5 stars$58.13+2.9%$72.94+25.5%-21.4%$10.76B$2.69B-49.686,600EXELExelixis4.6009 of 5 stars$35.28-2.1%$33.75-4.3%+61.0%$10.08B$2.08B22.621,310Analyst RevisionRGENRepligen3.8286 of 5 stars$156.94+1.3%$185.20+18.0%-9.8%$8.79B$639.92M-424.152,020HALOHalozyme Therapeutics4.6454 of 5 stars$54.47+3.2%$60.89+11.8%+60.5%$6.93B$947.36M18.04390Short Interest ↑MDGLMadrigal Pharmaceuticals4.5412 of 5 stars$300.68-11.3%$350.83+16.7%+29.7%$6.56B$76.81M-11.9990Insider TradeAnalyst RevisionHigh Trading VolumeIONSIonis Pharmaceuticals4.1296 of 5 stars$34.97+4.5%$60.65+73.4%-38.3%$5.52B$803.07M-14.33800Insider Trade Related Companies and Tools Related Companies United Therapeutics Alternatives Neurocrine Biosciences Alternatives Incyte Alternatives BioMarin Pharmaceutical Alternatives Exact Sciences Alternatives Exelixis Alternatives Repligen Alternatives Halozyme Therapeutics Alternatives Madrigal Pharmaceuticals Alternatives Ionis Pharmaceuticals Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ALKS) was last updated on 1/20/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMust-See: 5-Second Trump PredictionPresident Trump's prediction is about to become a reality... Opening a rare window of opportunity for you t...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredWarren Buffett Bets $40 Billion—You Can Get in for $20I call it "The Last Retirement Stock You'll Ever Need." Warren Buffett himself owns $40 billion of stock in...Behind the Markets | SponsoredKamala’s final humiliation The investments connected to Trump's second term in ways that almost nobody outside his inner circle is aware ...Porter & Company | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alkermes plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Alkermes With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ALKS Stock Alerts